Relapsed after standard therapy
Showing 1 - 25 of >10,000
Leukemia, Myeloid, Acute Trial in United States (Liposomal Annamycin)
Completed
- Leukemia, Myeloid, Acute
- Liposomal Annamycin
-
La Jolla, California
- +3 more
Feb 28, 2022
Lymphoma Non-Hodgkin Trial in Japan (Copanlisib (BAY80-6946))
Completed
- Lymphoma Non-Hodgkin
- Copanlisib (BAY80-6946)
-
Nagoya, Aichi, Japan
- +12 more
Feb 21, 2022
Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is
Completed
- Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate
- Test Product (Bendamustine)
-
Long Beach, California
- +9 more
Jun 2, 2021
Small Cell Lung Cancer (SCLC) Trial (Tarlatamab, Lurbinectedin, Topotecan)
Not yet recruiting
- Small Cell Lung Cancer (SCLC)
- Tarlatamab
- +3 more
- (no location specified)
Feb 21, 2023
Relapsed/Refractory Follicular Lymphoma Trial in Nashville (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Axicabtagene Ciloleucel
- +8 more
-
Denver, Colorado
- +6 more
Dec 2, 2022
Follicular Lymphoma (FL) Trial (biological, drug, other)
Not yet recruiting
- Follicular Lymphoma (FL)
- Tisagenlecleucel
- +4 more
- (no location specified)
May 24, 2023
Acute Myeloid Leukemia in Children Trial in Saint Louis (CIML NK Cell Infusion, CD3+ T Cell Product Infusion)
Recruiting
- Acute Myeloid Leukemia in Children
- CIML NK Cell Infusion
- CD3+ T Cell Product Infusion
-
Saint Louis, MissouriWashington University School of Medicine
Oct 26, 2022
Osteosarcoma in Children Trial (Dinutuximab beta)
Not yet recruiting
- Osteosarcoma in Children
- Dinutuximab beta
- (no location specified)
Sep 23, 2022
Gastrointestinal Cancer Trial (Capecitabine, Sacituzumab govetican)
Not yet recruiting
- Gastrointestinal Cancer
- Capecitabine
- Sacituzumab govetican
- (no location specified)
Oct 2, 2023
PTSD Trial in Mount Pleasant (3,4-methylenedioxymethamphetmine (MDMA), Therapy)
Completed
- Posttraumatic Stress Disorder
- 3,4-methylenedioxymethamphetmine (MDMA)
- Therapy
-
Mount Pleasant, South CarolinaOffices of Michael Mithoefer
Jun 14, 2022
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in United Kingdom (Epcoritamab, Lenalidomide, Rituximab)
Not yet recruiting
- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma
- Epcoritamab
- +10 more
-
Aberdeen, United Kingdom
- +24 more
Apr 28, 2023
Non-Hodgkin Lymphoma, Large B-cell Lymphoma Trial in Palo Alto (Axicabtagene Ciloleucel)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Large B-cell Lymphoma
- Axicabtagene Ciloleucel
-
Palo Alto, CaliforniaStanford University
Mar 20, 2023
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022
Not yet recruiting
- Cancer
- Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Fludarabine (30 mg/m^2)
- +2 more
- (no location specified)
Jul 25, 2023
Non Small Cell Lung Cancer Metastatic Trial in Worldwide (GEN1046, Pembrolizumab)
Recruiting
- Non Small Cell Lung Cancer Metastatic
- GEN1046
- Pembrolizumab
-
Santa Rosa, California
- +26 more
Jan 30, 2023
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)
Recruiting
- Relapsed Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Nivolumab
- Pembrolizumab
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022
Carotid Stenosis, Cognitive Impairment, Hyperbaric Oxygen Therapy Trial (procedure, drug, behavioral)
Not yet recruiting
- Carotid Stenosis
- +3 more
- Hyperbaric oxygen therapy
- +2 more
- (no location specified)
Aug 6, 2023
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Low Dose Radiation Therapy)
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Low Dose Radiation Therapy
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment Trial in Zhoukou, Tianjin (Linperlisib)
Not yet recruiting
- Autoimmune Hemolytic Anemia
- Failure of Two Rounds of Treatment
-
Zhoukou, Henan, China
- +1 more
Jan 7, 2023
High-Risk Neuroblastoma Trial in Krakow (Chemoimmunotherapy (Dinutuximab beta in combination with chemo))
Recruiting
- High-Risk Neuroblastoma
- Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)
-
Krakow, Malopolska, PolandUniversity Children Hospital
Mar 8, 2022
Upper Extremity Paresis, Stroke Trial in Jinan (individualized intermittent theta burst sitmulation (iTBS), standard iTBS, sham
Not yet recruiting
- Upper Extremity Paresis
- Stroke
- individualized intermittent theta burst sitmulation (iTBS)
- +2 more
-
Jinan, Shandong, ChinaQilu hospital of Shandong University
Nov 19, 2023
Breast Cancer, Early Breast Cancer Trial (Camizestrant, Tamoxifen, Anastrozole)
Not yet recruiting
- Breast Cancer, Early Breast Cancer
- Camizestrant
- +4 more
- (no location specified)
Mar 7, 2023
Variceal Hemorrhage Trial in Chandigarh (Terlipressin, 0.9% normal saline (NS))
Not yet recruiting
- Variceal Hemorrhage
- Terlipressin
- 0.9% normal saline (NS)
-
Chandigarh, IndiaDepartment of Internal Medicine, Post Graduate Institute of Medi
Aug 31, 2023
Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in Milwaukee (Belantamab mafodotin)
Recruiting
- Refractory Multiple Myeloma
- Relapse Multiple Myeloma
- Belantamab mafodotin
-
Milwaukee, WisconsinFroedtert & the Medical College of Wisconsin
Aug 3, 2022
HER2-overexpressed Advanced Solid Tumors After Progression of
Not yet recruiting
- HER2
- +3 more
- Disitamab Vedotin
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Dec 14, 2022